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Abstract 
Mitochondria play a key role in oncogenesis and constitute one of the most important targets 
for cancer treatments. Although the most effective way to deliver drugs to mitochondria is by 
covalently linking them to a lipophilic cation, the in vivo delivery of free drugs still constitutes 
a critical bottleneck. Herein, we report the design of a mitochondria-targeted metal-organic 
framework (MOF) that greatly increases the efficacy of a model cancer drug, reducing the 
required dose to less than 1% compared to the free drug and ca. 10% compared to the non-
targeted MOF. The performance of the system is evaluated using a holistic approach ranging 
from microscopy to transcriptomics. Super-resolution microscopy of MCF-7 cells treated with 
the targeted MOF system reveals important mitochondrial morphology changes that are 
clearly associated with cell death as soon as 30 minutes after incubation. Whole transcriptome 
analysis of cells indicates widespread changes in gene expression when treated with the MOF 
system, specifically in biological processes that have a profound effect on cell physiology and 
that are related to cell death. We show how targeting MOFs towards mitochondria represents 




While the survival rate for most cancers has doubled over the past 40 years, some cancers such as 
those of the pancreas, brain, lung and esophagus still have very poor prognoses. To improve cancer 
therapies, an enormous effort has been directed at obtaining a better fundamental understanding of 
the mechanisms of cancer growth and the differences in the metabolism between healthy and cancer 
cells. In particular, it is known that mitochondria play a key role in oncogenesis and thus constitute 
promising targets for novel cancer treatments1. Mitochondria are the energy powerhouse of cells; 
non-cancerous, healthy mammalian cells normally produce their energy by oxidative 
phosphorylation using the electron transport chain in the mitochondrial matrix. Cancerous cells, 
however, utilize glycolysis, even in the presence of oxygen2. This is due in part to a reprogramming 
of mitochondrial function in cancer cells that increases pyruvate dehydrogenase kinase (PDK) 
activity, which limits the uptake of pyruvate at a level necessary for oxidative phosphorylation3. 
 In addition to cellular metabolism, and related to novel cancer treatments, mitochondria are 
involved heavily in the regulation of cell death. Evasion of cell death is a trademark feature of 
cancer4 and is a determining factor in the growth of tumor cell populations5. Apoptosis, part of the 
cell death machinery, mostly involves proteases known as caspases (CASP), which are only 
activated when cell death is triggered. Permeabilization of the mitochondrial outer membrane 
triggers the caspase cascade, making treatment strategies that cause mitochondrial permeabilization 
attractive6–8. This is especially true given that the mitochondria of cancer cells are structurally and 
functionally different than those of their healthy cell counterparts and are more susceptible to 
perturbations9, making mitochondrial targeting a means to also selectively target cancer cells. As 
such, targeting cancer cells specifically and reverting their mitochondrial metabolism to oxidative 
phosphorylation as well as activating apoptosis is an attractive strategy in cancer treatment. 
The use of nanotechnology to design drug delivery systems (DDSs) has made significant 
strides in cancer therapies by improving the pharmacokinetics and bio-distribution of therapeutic 
agents10. Advances in nanoformulations allow the delivery of drugs in their pristine form, the 
solubilization of hydrophobic drugs, an increase in their half-life and a reduction of their side 
effects and immunogenicity. Among DDSs, functional nanoparticles are attractive candidates for 
selective targeting due to the possibility of modifying their external surfaces. Metal-organic 
frameworks (MOFs) in particular have arisen in the last years as favorable candidates for 
nanomedicine applications, owing to their unique properties11–17. Indeed, among the more than 
90,000 structures reported in the Cambridge Structural Database, many MOFs show high porosity 
and very large surface areas (as high as 8,000 m2/g), along with a highly tunable surface chemistry 
and pore size18. In addition, the synthesis of MOFs allows fine control over particle size and shape, 
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which is difficult to achieve with other systems. To date, a number of therapeutics have been 
encapsulated in MOFs, including anticancer, antibacterial and antiviral drugs, as well as nucleic 
acids and biological gases 19–24. We have previously demonstrated that it is possible to extend the 
release of cargo from the MOF framework by collapsing its porosity around the payload, either 
mechanically25,26 or thermally14. We have also demonstrated that it is possible to easily 
functionalize the external surface of MOFs to enhance their colloidal stability and immunogenecity, 
and improve their cellular uptake by directing them to clathrin or caveolae-mediated endocytic 
pathways16,27,28. We have also shown that it is possible to design MOFs to obtain clinically relevant 
nanoparticulate DDSs that are able to bypass lysosomal degradation28. In addition, a number of 
studies have shown the attachment of small molecules and peptides to specifically target cancerous 
cells29–32. Very recently, some studies have demonstrated a high level of mitochondrial targeting 
that resulted in improved efficacy of microwave-assisted thermal33 and radio/radiodynamic 
therapy34. 
Here, we report the design and testing of a Zr-MOF, UiO-66 (UiO = Universitetet i Oslo), 
loaded with the cancer drug dichloroacetate (DCA) and conjugated with triphenylphosphonium 
(TPP), which localizes to mitochondria. On the one hand, DCA is a small molecule that inhibits 
PDK, reversing cancer cell metabolism from aerobic glycolysis to oxidative phosphorylation35. This 
shift is accompanied by a downregulation of the abnormally high mitochondrial membrane 
potential, reduced proliferation and increased apoptosis of cancerous cells35,36. However, the 
hydrophilicity of DCA means that it does not efficiently cross cell membranes and so must be 
administered as part of a DDS to show any significant efficiency. On the other hand, TPP is a 
lipophilic cation that exhibits a single positive charge resonance-stabilized over three phenyl groups 
and a large hydrophobic area37. TPP is known to accumulate readily in mitochondria of living cells, 
driven by the mitochondrial membrane potential38–40. We have combined the design of the DDS and 
in vitro experiments with super-resolution microscopy in order to detect mitochondrial 
morphological changes associated with autophagy and cell death in unprecedented detail. We also 
reveal the genome-wide changes in transcription, related to cell death and metabolism, using a 
whole-transcriptome analysis of cells treated with our system. Altogether, using this holistic 
approach, our obtained data clearly indicate a profound enhancement of the therapeutic efficacy of 
DCA by the NPs presented here.  
Results and discussion 
Zirconium-based MOFs such as UiO-66 are a promising option for drug delivery, given the low 
toxicity of its components17 and large porosity (SBET = 1200 m
2g-1, Vp = 0.5 cm
3g-1). The pristine 
structure of this MOF consists of Zr-oxo clusters linked together by BDC units to give the overall 
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composition [Zr6O4(OH)4(BDC)6]n. The stability of UiO-66 in water and in vivo environments is 
also critical.41,42 We have shown in the past that UiO-66 shows general good stability in water but it 
is quickly degraded in the presence of phosphate salts (e.g. PBS), although in growth media the 
stability is enhanced due to the formation of a protein corona around the particles.17 Moreover, the 
specific use of DCA as a defect-inducing modulator is also known to enhance aqueous colloidal 
stability.43 To find a UiO-66 system with optimal mitochondrial targeting properties, we first 
synthesized three materials using DCA as a modulator, which is trapped in significant quantities at 
defect sites and the particle outer surfaces30. We named the materials DCAx-UiO-66, where x is the 
molar equivalent of DCA relative to the linker in the initial reaction conditions. Second, we 
attached 4-carboxybutyltriphenylphosphonium (TPP) post-synthetically to their external surface; we 
named these materials TPP@(DCAx-UiO-66). Third, we synthesized a separate UiO-66 sample 
with both DCA and TPP as modulators hence incorporating them during the synthesis; we called 
this sample DCA5-TPP5-UiO-66. Supplementary Figure S1 shows the powder X-ray diffraction 
(PXRD) patterns for the samples compared with the pattern predicted from the single crystal 
structure, confirming the crystallinity of UiO-66 irrespective of whether TPP is incorporated during 
the synthesis procedure or afterwards. Table 1 shows the particle sizes of the materials determined 
from SEM (Supplementary Figure S2), the colloidal analysis obtained from dynamic light 
scattering (DLS) in water as well as the DCA and TPP loadings, calculated by inductively coupled 
plasma optical emission spectroscopy (ICP-OES); Supplementary Figures S3 and S4 show the 1H 
NMR spectra and TGA profiles. Particle sizes as determined from SEM range from 81 nm to 139 
nm for DCA10-UiO-66 and DCA2.5-UiO-66, respectively, and are within the correct size range for 
cellular uptake. DCA loadings range from 1.2 to 15.5 wt.% whereas TPP loadings range between 
2.3 and 15.0 wt.%. Unsurprisingly, TPP loadings were much higher when added post-synthetically 
but the DCA loading was reduced, probably due to additional steps in the overall synthesis. 
Supplementary Figures S5 and S6 show the FTIR spectra and Supplementary Figure S7 shows 
the N2 adsorption isotherms at 77 K. 
Table 1 | Characterization of the UiO-66 based drug delivery system particles. Particle size, 

















DCA10-UiO-66 81 ± 27 257 ± 1 0.17 35.4 15.5 0 
DCA5-UiO-66 115 ± 48 308 ± 1 0.17 35.3 10.0 0 
DCA2.5-UiO-66 139 ± 51 348 ± 4 0.21 35.5 6.1 0 
DCA5-TPP5-UiO-66 131 ± 51 660 ± 26 0.51 42.2 13.0 2.3 
TPP@(DCA10-UiO-66) 81 ± 27 302 ± 2 0.28 9.3 2.2 14.6 
TPP@(DCA5-UiO-66) 115 ± 48 394 ± 6 0.35 12.9 1.2 7.0 
TPP@(DCA2.5-UiO-66) 139 ± 51 471 ± 10 0.35 10.0 1.5 15.0 
aMeasured by SEM – errors represent standard deviation of 100 particles. bMeasured by DLS in water. 
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In addition to particle size, colloidal stability is critical for intracellular delivery applications. 
DCA10-UiO-66, DCA5-UiO-66, and DCA2.5-UiO-66 have hydrodynamic diameters of 257, 308 and 
348 nm in water, respectively, with polydispersity (PdI) values ranging from 0.17-0.21 (Table 1). 
Also, the addition of TPP post-synthetically (i.e. TPP@(DCAx-UiO-66) samples) shows a slight 
increase (18-23%) in hydrodynamic diameter compared to pristine DCAx-UiO-66 samples, with 
PdI values ranging from 0.28 to 0.35. The only exception is TPP@(DCA2.5-UiO-66), with an 
increment in hydrodynamic diameter of 35 and 40%, respectively. Even though the hydrodynamic 
diameters for all the particles increase compared to SEM, they remain within the size range that 
cells can take up by endocytosis, while still displaying good colloidal stability in pure water. DCAx-
UiO-66 samples show similar z-potential values, at around 35.4 mV, whereas the post-synthetic 
addition of TPP decreases it to 7.9-15.1 mV (Table 1). This, however, does not affect the colloidal 
stability of the particles, as shown by PdI values below 0.36. The only exception here is DCA5-
TPP5-UiO-66, which, despite the high z-potential of 42.2 mV, has lower colloidal stability, with a 
PdI of 0.51. It is notable that post-synthetic loading of TPP gives much higher incorporation (7-15% 
w/w) than direct inclusion of TPP in MOF synthesis, but also leads to a significant loss of DCA 
cargo, suggesting detachment under these conditions. In our post-synthetic modification, reduction 
of the zeta potential can only be related to changes in the external surface chemistry; for example, 
related to the loss of DCA and linker molecules. Zeta potentials in MOFs have proven to be very 
difficult to interpret as there is a large number of factors that affect it due to its porous and 
coordination nature. In particular, the bulk chemistry greatly affects the external surface chemistry 
and is dependent on factors such as the number of defects and the constituent molecules forming the 
porosity. In the past, we have observed large variations of the zeta potential in UiO-66 samples to 
similar values to the ones we observed here, corroborating our observations.40 
 To investigate the cytotoxicity of the different materials, we first ran an MTS assay for MCF-7 
cells, analyzing it against both the DDS and DCA concentrations to determine whether the observed 
toxicity is due to DCA alone or other properties inherent to the DDS (Figure 1a). When plotted 
against DDS concentration, DCA10-UiO-66 and DCA5-UiO-66 have a comparable effect on MCF-7 
cells, decreasing viability to ca. 67% at 1 mg/mL, whereas DCA2.5-UiO-66 and DCA5-TPP5-UiO-
66 have a more pronounced effect with 48 and 36% viability, respectively. When plotted against 
DCA concentration, however, the different samples have different effects on cell viability, 
indicating that toxicity is not solely dependent on DCA concentration. Factors such as particle size 
and surface chemistry have been shown to play a role in determining the cellular uptake efficiency 
and endocytosis pathways that nanoparticles use to enter cells.28,44 Since the different samples have 
different physicochemical properties, and because of the low loading of TPP (2.3% w/w) by direct 
incorporation into synthesis, it is difficult to isolate the effect of TPP as a targeting functionality. 
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Direct incorporation may also result in localization of TPP throughout the porosity of the MOF, and 
not solely at the particle external surface, further reducing any targeting effect.  
 
Figure 1 | MTS viability assay of MCF-7 cells after incubation with different systems. a, cell viability as 
a function of DDS (top) and equivalent DCA concentration (bottom) after incubation for 72 h with different 
DCA-loaded DDSs. b, cell viability as a function of DDS (top) and equivalent DCA concentration (bottom) 
after incubation for 72 h with DCAx-UiO-66 and TPP@(DCAx-UiO-66). c, cell viability as a function of 
DDS (top) and equivalent DCA concentration (bottom) after incubation for 4-72 h with DCA5-UiO-66, 
TPP@(DCA5-UiO-66) and DCA5-TPP5-UiO-66. Error bars – sometimes smaller than the symbol sizes – 
represent the standard error of the mean of five replicate measurements.     
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To control for the effect of particle size and isolate the effect of TPP as a targeting agent, we 
then investigated the cytotoxicity of the post-synthetically modified samples, again, as a function of 
DDS and DCA concentration (Fig. 1b). Looking at the cell viability reduction, with values ranging 
35 to 23% at 1 mg/mL (Fig. 1b, top), the addition of TPP to the external surface dramatically 
increases the cytotoxicity of the materials by mitochondrial targeting. When plotted against 
equivalent DCA concentration, the effect is even more important, where the cell viability was 
dramatically reduced even at low concentrations of DCA (Fig. 1b, bottom). Importantly, in TPP 
samples, we required a ca. 10-fold lower concentration of DCA, compared to non-targeted DCAx-
UiO-66, to achieve the same reduction in viability. To validate the hypothesis of the synergistic 
effect of TPP, DCA and UiO-66, Figure S7 shows the cytotoxicity of the DCA drug alone, TPP 
alone, DCA+TPP, naked UiO-66 and UiO-66 transporting TPP (i.e. TPP@MOF). The results show 
that the individual molecules and the TPP@MOF were not toxic up to concentrations of 1 mg/mL, 
confirming previous examples in the literature.45,46,47 All this proves that the increase in toxicity is 
due to the drug delivery vehicle targeting to mitochondria. 
We investigated further the mitochondrial targeting abilities of TPP@(DCA5-UiO-66) and 
DCA5-TPP5-UiO-66; we included DCA5-UiO-66 as a non-targeted control. In order to verify the 
structural information and the homogeneity of the loaded MOFs, we ran transmission electron 
microscopy (TEM) and X-ray photoelectron spectra (XPS) measurements on these three samples. 
Supplementary Figure S8 shows the TEM images, confirming the sizes of the particles obtained 
from SEM; Supplementary Table S1 shows the external surface composition (atomic %) for the 
three samples, DCA5-UiO-66, TPP@(DCA5-UiO-66) and DCA5-TPP5-UiO-66, and Figures S9-
S10 show a detailed analysis of the C1s, O1s, Zr3d, P2p and Cl2p regions. All samples contain C, O 
and Zr coming preferentially from the MOF network, while P is detected only for samples 
containing TPP, and Cl is detected from DCA. These results confirm the successful incorporation of 
TPP and DCA in the UiO-66 formulation. A closer look at these values shows that the Cl 
percentage is slightly larger for sample DCA5-UiO-66 compared to DCA5-TPP5-UiO-66 (2.5 at.% 
vs. 2.1 at.%), in agreement with ICP-OES analysis. DCA5-TPP5-UiO-66 also shows a certain 
amount of P (0.1 at.%), thus confirming the successful incorporation of TPP in the formulation. 
Interestingly, the post-synthesis modification of DCA5-UiO-66 with TPP gives rise to important 
changes. The percentage of P increases to 0.3 wt.%, while the amount of Cl goes down to 0.5 wt.%. 
This observation suggests that TPP is mainly located at the MOF external surface, while DCA 
either remains in the inner porosity (not detectable by XPS) or it is detached from the structure after 
TPP incorporation. Another important finding after TPP incorporation is the significant decrease in 
the amount of C and the increase in the amount of Zr and O. These observations could be associated 
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with changes in the surface structure during the incorporation of the TPP targeting unit. These 
changes can be more clearly appreciated in the O1s region (Figure S9). 
Figure 1c shows the time-dependent MTS viability in order to determine the kinetics of 
toxicity of the three MOFs on MCF-7 cells both as a function of DDS and DCA concentration. For 
the two materials containing TPP, we observe toxicity as early as 4 h. At DDS concentration of 1 
mg/mL, viability decreases to 78% and 66% for DCA5-TPP5-UiO-66 and TPP@(DCA5-UiO-66), 
respectively, decreasing further as time progresses but stabilizing between 8 and 48 h down to 
values of ca. 60 - 50%. At 72 h, viability reduces further down to 36 and 12% for both MOFs at 1 
mg/mL concentration. DCA5-UiO-66, on the other hand, remains non-toxic up to 48 h, showing 
only slight toxicity after 72 h at the highest concentration of 1 mg/mL (viability ca. 63%). When 
plotted as a function of DCA concentration, it is clear that TPP@(DCA5-UiO-66), which has the 
lowest levels of DCA loading and TPP present only on the external surface, is the most toxic 
material, causing a sharp decrease in cell viability after as soon as 4 h of incubation. Interestingly, 
when comparing the toxicity of DCA5-TPP5-UiO-66 and DCA5-UiO-66 based on DCA 
concentration, they show similar performance for times below 72 h. At 72 h, DCA5-TPP5-UiO-66 
seems to be more active than DCA5-UiO-66. Whereas it is clear that the addition of TPP to the 
external surface dramatically increases the efficacy of the UiO-66-based DDS, its addition during 
the UiO-66 synthesis does not show the same benefits. This is probably because TPP loading is 
much lower, and it may be integrated throughout the MOF matrix and therefore cannot target the 
particles to the mitochondria – showing only a beneficial effect at 72 h, perhaps due to the partial 
degradation and release of TPP to the media. This observation of the TPP located on the external 
surface area was confirmed by XPS, as described above. 
To confirm that TPP is directing the DDS to the mitochondria, we first tracked the particles in 
vitro, imaging them with a modified fluorescent pyrene group on the TPP (fTPP), creating 
fTPP@(DCA5-UiO-66). Figure 2a shows the confocal images of MCF-7 cells after 2 h of 
incubation with fTPP@(DCA5-UiO-66). Mitochondria are represented in red, and nuclei in blue. In 
the merged images, we observe some co-localization between fTPP@(DCA5-UiO-66) and RFP-
labelled mitochondria, as illustrated by the yellow color (shown by white arrows). Additionally, 
most of the non-overlapping signal originating from fTPP@(DCA5-UiO-66) is heavily concentrated 
around the mitochondria. This suggests that the DDS is being targeted without necessarily being 
completely taken up by mitochondria, possibly due to the size of the DDS being too large for 
mitochondrial uptake. Given the observed cytotoxic effect, mitochondrial uptake might not be 
necessary to observe an increase in the efficacy of DCA. The mere accumulation of particles near 




Figure 2 | Microscopy imaging of MCF-7 cells. a, confocal microscopy images of cells incubated for 2 h 
with fTPP@(DCA5-UiO-66); b, SIM images of cells incubated for 30 min (left) and 8 h (right) with cal-
TPP@(DCA5-UiO-66). fTPP and calcein are shown in green, mitochondria stained with RFP are shown in 
red and nuclei stained with DRAQ-5TM are shown in blue. White arrows in confocal microscopy show 




To better visualize the internalization of the MOF and to better determine the existence of co-
localization, we imaged the cells using structured illumination microscopy (SIM). Since the SIM 
microscope is incompatible with UV lasers, we could not use fTPP to track our system, so we 
loaded the MOF with the fluorescent molecule calcein instead. We named the resulting MOF cal-
TPP@(DCA5-UiO-66). Figure 2b shows 3-colour images of cells in the presence of cal-
TPP@(DCA5-UiO-66) after 30 min and 8 h incubation. These images show that the DDS is taken 
up by cells, as early as 30 min after incubation, shown by the fact that the red-colored mitochondria 
and green spots of MOF particles are in focus in the same plane. After 8 h, cells take up a 
considerably larger amount of MOF. In terms of co-localization with the DDS, it is difficult to 
decipher from the images whether the MOF is distributed close to mitochondria or not. This is 
because mitochondria are large organelles that occupy up to 25% of the cytoplasm. However, some 
interesting morphological changes, which can be indicative of cellular health48, are apparent. 
Whereas healthy cells are expected to have elongated mitochondria that form reticular networks, for 
cells treated with cal-TPP@(DCA5-UiO-66), most mitochondria have a balloon-shaped morphology 
and are notably shorter in length.  
To probe the effect of the targeted DDS on mitochondrial morphology further, we incubated 
MCF-7 cells with both targeted and non-targeted MOFs loaded with calcein. We called this new 
sample cal@(DCA5-UiO-66). Figure 3a shows the SIM images of untreated and incubated cells 
after 8 h. In the case of untreated cells, mitochondria are elongated and form reticular networks, as 
expected (Fig. 3a, left). On the other hand, cells incubated with cal-TPP@(DCA5-UiO-66) have 
short, balloon-shaped mitochondria (Fig. 3a, right). For cells incubated with cal@(DCA5-UiO-66), 
while mitochondria show some fragmentation, the effect is less severe than with cal-TPP@(DCA5-
UiO-66) and they still remain partially stringy and reticular, as shown by the white arrows (Fig. 3a, 
center). Importantly, mitochondrial morphology is very dynamic by nature; depending on cellular 
requirements, they are recycled in a dynamic equilibrium between opposing processes of fission and 
fusion49. Fusion produces extended interconnected mitochondria that form reticular networks, while 
fission produces shorter, balloon-shaped, fragmented mitochondria. Fission is required to control 
cell quality by replacing damaged mitochondria and also facilitates apoptosis during high levels of 
cellular stress50. These morphological dynamics, as well as the spatial localization of mitochondria 
inside the cell, are heavily linked to mitochondrial and cellular function, with a good balance of 
fission and fusion required to maintain general cellular functionality. Kamogashira et al. for 
example have demonstrated a fundamental interdependence between mitochondrial metabolic 
activity and its network structure50. The fact that fragmentation of mitochondria increases upon 
exposure to the targeted DDS indicates an imbalance between fission and fusion (fission > fusion). 
Some studies50,51 have demonstrated a direct link between mitochondrial fission and mitochondrial 
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degradation through mitophagy – a mechanism by which impaired or damaged mitochondria are 
encapsulated in autophagosomes that then fuse with lysosomes where they are degraded. 
Interestingly, fragmentation of mitochondria – indicating mitochondrial damage – is observed as 
early as 30 min after incubation with the targeted DDS studied here (Fig. 2b).  
 
Figure 3 | SIM imaging of MCF-7 cells. a, images of untreated cells and cells treated with cal@(DCA5-
UiO-66) and cal-TPP@(DCA5-UiO-66) for 8 h; mitochondria are colored in red, MOFs in green, and nuclei 
in blue; white arrows indicate stringy mitochondria. b, images showing a shape analysis of mitochondria 
using Cell Profiler software. Top row, untreated cell; bottom row, cell after 8 h incubation with cal-
TPP@(DCA5-UiO-66). c, the effects of different treatments on the eccentricity of mitochondria. Results 
show the average eccentricity of at least 200 mitochondria. Error bars represent the standard error of the 
mean. Statistical significance was assessed using one-way ANOVA followed by Tukey’s multiple 
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To quantify mitochondrial fragmentation, we assessed the eccentricity of each mitochondrion 
and assigned to it a value between 0 and 1, the eccentricity of a circle being 0 and that of an ellipse 
that is not a circle greater than 0 and less than 1. Figure 3b shows representative images of the 
original SIM as well as of mitochondria objects identified by the Cell Profiler pipeline; Figure 3c 
shows the quantification of the average eccentricity value for untreated cells, cells treated with cal-
TPP@(DCA5-UiO-66) for 30 min and 8 h, and cells treated with cal@(DCA5-UiO-66) for 8 h. The 
value for each treatment represents the average of at least 200 mitochondria. As expected, healthy 
cells have the most eccentric mitochondria (0.819 ± 0.010). The larger error bars are indicative of a 
wide distribution of eccentricity, which is consistent with the fact that mitochondria in healthy cells 
have a dynamic balance between fission and fusion. Cells treated with cal@(DCA5-UiO-66) for 8 h 
have an average eccentricity 0.793 ± 0.005, which is not significantly different than the untreated 
control. For cells treated with cal-TPP@(DCA5-UiO-66), the eccentricity of the mitochondria is 
significantly reduced to 0.768 ± 0.004 after 8 h (p = 0.0002), indicating that the TPP-containing 
DDS has an effect on mitochondrial morphology. Interestingly, treatment with cal-TPP@(DCA5-
UiO-66) for only 30 min also leads to a statistically significant change in mitochondrial eccentricity 
compared to untreated cells (0.786 ± 0.005; p = 0.0267), demonstrating that the system has a very 
rapid effect on cells. Treatment with the targeted DDS, therefore, seems to reduce mitochondrial 
fusion, leading to smaller mitochondrial entities, with a large number of small clusters present in the 
mitochondrial network attributable to the formation of autophagosomes. 
To determine whether TPP@(DCA5-UiO-66) is more toxic than DCA5-UiO-66 due to a 
difference in cellular uptake mechanism, we studied the uptake pathway, using pharmacological 
inhibitors, by which MCF-7 cells take up these two MOFs. The intracellular fate of particles is 
dependent on the endocytosis pathway they go through, with particles taken up through clathrin-
mediated endocytosis typically ending up in lysosomes where they are degraded along with their 
drug cargo, whereas particles going through caveolae-mediated endocytosis can sometimes be 
released into the cytosol and avoid lysosomal degradation 28,44. Figure 4a shows MCF-7 cells’ 
internal fluorescence after incubation with the two MOFs in the presence of different endocytic 
inhibitors. To determine if the differences were statistically significant, we compared every value to 
the control at 37 C using ANOVA followed by Dunnett’s test to adjust for multiple comparisons. 
When incubated at 4 C, cellular uptake of the MOFs was significantly reduced by ca. 80% for 
cal@(DCA5-UiO-66) and ca. 60% for cal-TPP@(DCA5-UiO-66). Cellular metabolism is greatly 
slowed down at this temperature, which confirms that the particles are taken up by the active 
mechanism of endocytosis. When incubated with chlorpromazine (clathrin-mediated endocytosis), 
MOFs uptake did not decrease significantly for cal@(DCA5-UiO-66), whereas there was a 
moderate decrease to 69% for cal-TPP@(DCA5-UiO-66). When incubated with hypertonic sucrose, 
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particle uptake decreased significantly to 28% and 40% for cal@(DCA5-UiO-66) and cal-
TPP@(DCA5-UiO-66), respectively. Although sucrose is a known inhibitor of clathrin-mediated 
endocytosis, there is evidence suggesting that it is non-specific, which might explain why we 
observed a much larger degree of inhibition when cells were incubated with sucrose as compared to 
chlorpromazine. Inhibition with nystatin (caveolae-mediated endocytosis) showed no statistically 
significant decrease in intracellular fluorescence with respect to the controls for both DDSs. 
Rottlerin (macropinocytosis) significantly decreased the uptake of cal@(DCA5-UiO-66) to 56%, 
whereas it did not affect the uptake of cal-TPP@(DCA5-UiO-66). These results suggest that 
cal@(DCA5-UiO-66) is internalized mostly by clathrin- and caveolae- independent endocytosis, 
whereas cal-TPP@(DCA5-UiO-66) is internalized mostly by clathrin-dependent endocytosis. The 
literature offers conflicting data about the selection of endocytic pathways for charged particles. 
However, studies on HeLa cells using charged NPs support clathrin-mediated endocytosis for 
positively charged particles52, which might explain why adding TPP to the surface of the MOF 
leads to this internalization route. With regards to the final intracellular fate of the particles, we 
have previously shown that particles taken up by clathrin-dependent endocytosis end up being 
degraded in lysosomes along with their cargo, voiding their therapeutic effect28,44. However, 
TPP@(DCA5-UiO-66) is clearly able to reach its intended target despite being taken up by clathrin-
mediated endocytosis, as demonstrated by its toxicity to MCF-7 cells and the imaging studies. This 
could be due to the ability of positively-charged TPP to act as a proton sponge and promote 






Figure 4 | Final fate of MOF nanoparticles in MCF-7 cells. a, effects of pharmacological endocytosis 
inhibitors on the uptake of cal@(DCA5-UiO-66) (white bars) and cal-TPP@(DCA5-UiO-66) (red bars) by 
MCF-7 cells, measured by flow cytometry. b, Caspase 7, 8, and 9 activities after incubation of MCF-7 cells 
for 4 h and 8 h with DCA5-UiO-66, DCA5-TPP5-UiO-66 and TPP@(DCA5-UiO-66). Samples were run in 
triplicate; error bars represent the standard error of the mean. Statistical significance was assessed using one-
way ANOVA followed by Dunnett’s multiple comparisons test. 
At this point, we tested the hypothesis that the materials cause cell death by apoptosis. 
Dysregulation of apoptosis is a hallmark feature of most cancers and triggering it is, therefore, an 
attractive target for the design of cancer treatments. A family of proteases called caspases are 
heavily involved in the apoptotic process. We measured the activity of caspase-3/7, caspase-8, and 
caspase-9 after incubation with 0.5 and 1.0 mg/mL of MOF for 4 and 8 h; Figure 4b shows the 
fold-change in caspase activity compared to untreated cells. At a concentration of 0.5 mg/mL and as 
early as within 4 h, there is an increase in caspase-7 and caspase-8 activities for all the TPP-
containing materials, followed by a return to baseline at 8 h. DCA5-UiO-66, which does not contain 
TPP, shows no increase in caspase-7 and caspase-8 activities at both 4 and 8 h. There is virtually no 
increase in caspase-9 activity for all four materials at 4 and 8 h, with only DCA5-TPP5-UiO-66 
showing a slight increase in activity after 8 h. At the higher concentration of 1 mg/mL, even TPP-
absent DCA5-UiO-66 causes an increase in caspase-7 and caspase-8 activities. It is thought that 

































































































































































mitochondrial membrane, which then activates the executioner caspases 3/7. However, our results 
suggest an important role for caspase-8 and not for caspase-9. This has also been seen in several 
studies in which the roles of caspase-8 and caspase-9, as well as the temporal and hierarchical order 
of the caspase events, have been questioned. For instance, Ferreira et al. demonstrated the existence 
of a drug-inducible apoptosis pathway in which the activation of caspase-8 but not caspase-9 forms 
the apical step from which mitochondria-dependent apoptosis occurs53. Wieder et al. demonstrated 
a death-receptor-independent activation of caspase-8, slightly preceded by caspase-3 activation, and 
indicating that caspase-8 cleavage is a downstream event of post-mitochondrial caspase-3 
activation54. Pirnia et al. also demonstrated a caspase-9-independent, purely intracellular activation 
of caspase-8 when treating MCF-7 cells with mitomycin C55. 
Our phenotypic cell viability assays and imaging studies suggest that by successful 
mitochondrial targeting via our cargo system DCA, we can enhance cellular toxicity. This cellular 
toxicity varies according to the differences in the design of the targeting system. To uncover the key 
biophysical and biochemical cellular pathways triggered by the different treatments and confirm 
mitochondrial involvement, we performed microarray analysis on MCF-7 cells after exposure to the 
treatments for 72 h. We generated samples for microarray analysis by treating cells independently 
with the free drug DCA, or DCA incorporated into a MOF using three different systems: DCA5-
UiO-66, DCA5-TPP5-UiO-66 and TPP@(DCA5-UiO-66). More than 10,000 genes were detected 
for each comparison (Figure 5a). As expected, we did not detect any difference in the expressed 
genes (DEGs) when comparing cells treated with DCA to untreated cells (p < 0.05 or p < 0.01). 
This indicates that DCA at a concentration of 0.25 mg/mL does not have any apparent effect on the 
transcriptome after 72 h, i.e. that it does not alter MCF-7 gene expression. We observed the 
presence of 71 DEGs (p < 0.05) when using DCA5-UiO-66 compared to untreated cells; this 
number drops down to 3 DEGs when p < 0.01. Remarkably, both mitochondrially-targeted DDSs, 
i.e. DCA5-TPP5-UiO-66 and TPP@(DCA5-UiO-66), induced drastic widespread changes in gene 
expression profiles. DCA5-TPP5-UiO-66 caused significant changes in the expression level of 1,519 
genes (p < 0.05), of which 821 were up-regulated and 698 were down-regulated, and TPP@(DCA5-
UiO-66) affected the expression level of 910 genes (p < 0.05), of which 533 were up-regulated and 
377 were down-regulated. These results are consistent with the efficacy of these drugs that we 
observed in our cell viability assays where we found most toxicity in cells treated with DCA5-TPP5-







Figure 5 | Biochemical effects of different treatments on MCF-7 cells. a, Number of differentially 
expressed genes between cells treated with different conditions. b, Venn diagram analysis of differentially 
expressed genes in microarrays of MCF-7 cells treated with DCA5-UiO-66, DCA5-TPP5-UiO-66, and 
TPP@(DCA5-UiO-66) compared to untreated control. c, Gene network displaying interconnected genetic 
targets in common for all three treatments. d, Significant gene ontology (GO) terms of associated biological 
processes from 59 differentially expressed genes (p < 0.05) in MCF-7 cells in common for all three 
treatments (top), treated with TPP@(DCA5-UiO-66) (middle), and treated with DCA5-TPP5-UiO-66 
(bottom).  
Since the core component of our synthesized drug delivery systems is DCA, which varies in its 
efficacy due in part to the attached targeting agent, we performed Venn diagram analysis at p < 0.05 
to find gene targets which are common as well as exclusive to different treatments (Figure 5b). We 
found that 59 genes targets were common to treatments with DCA5-UiO-66, DCA5-TPP5-UiO-66 
and TPP@(DCA5-UiO-66). These 59 genes represented 84% of the genes differentially expressed 
by DCA5-UiO-66, with DCA5-TPP5-UiO-66 and TPP@(DCA5-UiO-66) affecting numerous 
additional genes (1460 and 851 respectively). This supports the results showing that the addition of 
TPP to the MOF increases the efficacy of DCA on MCF-7 cells.  Figure 5d shows a gene ontology 
(GO) analysis of the differentially expressed genes in MCF-7 after the different treatments. 
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Consistent with our phenotypic observations, analysis of the 59 common gene targets revealed the 
significant enrichment of GO terms such as cell death, apoptosis and programmed cell death. Since 
the efficacy of DCA5-TPP5-UiO-66 and TPP@(DCA5-UiO-66) was much higher than that of 
DCA5-UiO-66, we analyzed the gene targets that were exclusive to DCA5-TPP5-UiO-66 or 
TPP@(DCA5-UiO-66). GO analysis of the exclusive targets revealed the significant enrichment of 
biological processes, which have a more profound effect on cell physiology, such as transcription, 
chromatin modification, regulation of caspase activity and oxidative stress, although it is difficult to 
pinpoint exactly how much each component of the DDS participates in each effect with the current 
experimental setup. Interestingly, we also found significant enrichment of biological processes such 
as mitochondrial transport and mitochondrial membrane organization for the treatment with 
TPP@(DCA5-UiO-66), the most toxic system to cells. Next, we explored if there is any gene 
network, underlying the regulation of cell proliferation and survival, upregulated in cells treated 
with drugs. By using the STRING program56, we performed the functional protein association 
network analysis with all the genes that were significantly upregulated in cell treated with either of 
the drugs (Supplementary Figure S8) and extrapolating this network with the genes which have 
been reported to be functionally associated with the genes in our list. We identified a gene network 
(Figure 5c), common to all the three treatments, which is a part of the mTOR signaling pathway, 
the master regulator of cell metabolism, growth and survival. This gene network could be built 
mainly because of the gene RRAGD, a G protein which is crucial in activating mTOR signaling 
cascade, which was commonly targeted by all the three drugs. Taken together, our microarray 
analysis complements our phenotypic assays and consolidates our drug design strategy for 
successful targeting of mitochondria.  
Outlook 
We have demonstrated the successful development of a mitochondria-targeted metal-organic 
framework that greatly increases the efficacy of the anti-cancer agent DCA. This targeting effect is 
important for novel cancer treatments due to the key role of mitochondria in oncogenesis. In vitro 
viability studies suggest that targeting the delivery system to mitochondria greatly reduces the 
amount of the required drug to less than 1% compared to the free drug and ca. 10% compared to the 
non-targeted system. We have used a number of cutting-edge techniques to elucidate the 
biophysical and biochemical mechanisms of cell death. Using super-resolution microscopy, we 
demonstrate that the targeted MOF localize around mitochondria, causing morphological changes 
associated with toxicity when incubated with the mitochondria-targeted system – as soon as 30 
minutes after treatment – that can be observed in unprecedented detail. Cellular uptake studies 
showed no uptake through the caveolae-mediated route, suggesting an endolysosomal route to 
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degradation within the cell. The observed toxicity of the targeted system is nonetheless indicative of 
its ability to escape endosomes and reach mitochondria, something that could be attributed to the 
TPP acting as a proton sponge and allowing the rupture of endosomes. We then studied the changes 
in gene expression after treatment with the targeted MOF using a whole-transcriptome analysis; we 
used a microarray analysis on MCF-7 cells to examine the key biophysical and biochemical 
pathways triggered by the delivery systems, where we found widespread changes in gene 
expression. Key pathways affected are biological processes having a profound effect on cell growth, 
metabolism and survival. This work allowed us to uncover the effects of MOF-based delivery 
systems at the transcriptional level, validating observations seen at the functional level. Through 
this work, we show how the efficacy of existing drugs can be dramatically improved using this 
highly tunable material; our holistic approach uncovers the potential of MOF-based DDSs and 
fundamentally justifies their benefits as materials that can greatly enhance the therapeutic efficacy 
of drugs. Thinking globally, we propose this work to serve as a guideline for the exploration of 
future, targeted drug delivery vehicles. 
Methods 
Materials. ZrCl4 (99.5%) and terephthalic acid (98%) were purchased from Alfa Aesar (UK). 
Dichloroacetic acid (≥99%), HCl (37%), 4-carboxybutyl triphenylphosphonium bromide (98%), 3-
(diphenylphosphino)propionic acid (97%), 1-bromopyrene (96%), acetic acid (≥99%), 
dimethylformamide (DMF, 99.8%), methanol (99.9%), and acetone (99.9%) were purchased from 
Sigma-Aldrich (UK). Dulbecco’s modified Eagle’s medium (DMEM), foetal bovine serum (FBS), 
L-glutamine, penicillin, streptomycin, and CellLight™ Mitochondria-GFP BacMam 2.0 were 
purchased from Invitrogen (UK). DRAQ5™ stain was purchased from Abcam. Phosphate-buffered 
saline (PBS), trypsin–EDTA, and Lysotracker®-Deep Red were purchased from Life 
Technologies™ (UK). CellTiter 96® AQueous One Solution Cell Proliferation Assay (MTS) and 
Caspase-Glow® 3/7, 8, and 9 Assay Systems were obtained from Promega (UK). All chemicals and 
biochemicals used were of analytical grade. MCF-7 (ECACC 86012803) and HEK293 (ECACC 
85120602) cells were obtained from the ECACC. 
Synthesis of DCA5-TPP5-UiO-66. 10 mL of a DMF solution containing BDC (149.6 mg, 0.9 
mmol) and TPP (1995 mg, 4.5 mmol) were added to 10 mL of a DMF solution containing ZrCl4 
(209.6 mg, 0.9 mmol) in a 25 mL glass vial. HCl (80 µL, 0.9 mmol) and DCA (275 µL, 4.5 mmol) 
were added to the mixture. Next, the vials were sealed and put in an oven at 120 °C for 24 hours. 
The resulting powders were collected by centrifugation (5500 rpm, 15 minutes), and re-dispersed in 
10 mL DMF, followed by another centrifugation cycle. This two-step washing process was repeated 
two more times with DMF to remove the unreacted BDC, followed by two washes with methanol to 
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remove the DMF. The collected UiO-66 particles were finally dried at room temperature under 
vacuum overnight. The amounts of DCA and TPP incorporated in the structure were determined by 
ICP-OES. 
Synthesis of fTPP. Synthesis of fTPP was done according to a previously published protocol37. 1-
bromopyrene (1744 mg, 5.92 mmol) and 3-(diphenylphosphino)propionic acid (2296 mg, 8.88 
mmol) were dissolved in 64 mL toluene, and were then left to reflux overnight. The resulting 
yellow precipitate was hot-filtered, washed once with methanol, and then left to dry in a rotary 
evaporator, giving rise to a pale yellow solid (3.223 g, 98%). 
Post-synthetic attachment of TPP to UiO-66-DCA. 40 mg of UiO-66-DCA were dispersed in 20 
mL methanol and sonicated for 5 minutes. Separately, 40 mg of either 4-carboxybutyl-TPP or fTPP 
were dissolved in 20 mL MeOH, and 0.2 mL triethylamine was added to the mixture. The two 
solutions were then mixed and left to stir at room temperature overnight. The nanoparticles were 
collected by centrifugation, washed (x2) with methanol to wash off unattached TPP, and left to dry 
under vacuum at room temperature overnight. 
Powder X-ray diffraction (PXRD): PXRD measurements were carried out at 298 K using a 
PANalytical X’Pert PRO diffractometer (λ (CuKα) = 1.5418 Å) on a mounted bracket sample stage. 
Data were collected over the range 5–45°. 
Thermogravimetric analysis (TGA): Measurements were carried out using a TA Instruments 
Q500 Thermogravimetric Analyser. Measurements were collected from room temperature to 800 
°C with a heating rate of 10 °C/min under an air atmosphere.  
Dynamic light scattering: Colloidal analysis was performed by Dynamic light scattering (DLS) 
with a Zetasizer Nano ZS potential analyzer equipped with NonInvasive Backscatter optics (NIBS) 
and a 50 mW laser at 633 nm.   
ICP-OES: Zirconium, chlorine and phosphorus quantification was performed on a Thermo 
Scientific iCAP 7400 ICP-OES analyser against 1 ppm and 10 ppm standards. 
Nuclear Magnetic Resonance Spectroscopy (NMR): NMR spectra were recorded on either a 
Bruker AVIII 400 MHz spectrometer or a Bruker AVI 500 MHz spectrometer and referenced to 
residual solvent peaks.   
UV-Vis/Fluorescence Spectroscopy: UV-vis and fluorescence spectra were recorded using a 
Tecan Spark® Multimode Microplate Reader.  
Scanning Electron Microscopy (SEM): The powder samples were coated with Pd for 150 seconds 
using Polaron SC7640 sputter coater and imagined using a Carl Zeiss Sigma Variable Pressure 
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Analytical SEM with Oxford Microanalysis. 
Transmission Electron Microscopy (TEM): measurements were carried out on a FEI TECNAI 
F20 with an acceleration voltage of 200 kV. Samples were prepared by dropcasting a sonicated 
methanolic suspension on a 400 Mesh Cu grid. 
X-ray photoelectron spectra (XPS): Measurements were performed with a K-ALPHA 
spectrometer (Thermo Fisher Scientific, Waltham, MA, USA) operated in the constant energy mode 
with survey pass energies of 200 eV and narrow scan energies of 50 eV, to measure the whole 
energy band as well as selectively measure particular elements. XPS spectra were acquired using 
Al-Kα radiation (1486.6 eV) with a twin monochromator, yielding a focused X-ray spot at 3 mA x 
12 kV. Charge compensation was attained with the system flood gun, which provides low energy 
electrons and low energy argon ions from a single source. For the reference binding energy, the C1s 
core level was used, located at 284.6 eV. 
Confocal Microscopy: Measurements were carried out using Leica TCS SP5 confocal microscope. 
The microscope was equipped with 405 diode, argon and HeNe lasers. Leica LAS AF software was 
used to analyze the images. 
Super-Resolution Microscopy: Measurements were carried out using a custom-built 3-color 
Structured Illumination Microscopy (SIM) setup that has been described previously57. The 
structured illumination patterns were generated by a spatial light modulator (SLM: SXGA-3DM, 
Forth Dimension Displays). A 60x/1.2NA water immersion lens (UPLSAPO 60XW, Olympus) 
focused the structure illumination pattern onto the sample. This lens also captured the fluorescence 
emission from the sample, which was imaged onto a sCMOS camera (C11440 Hamamatsu). Laser 
excitation wavelengths used were 488 nm (iBEAM-SMART-488, Toptica), 561 nm (OBIS 561, 
Coherent), and 640 nm (MLD 640, Cobolt), to excite the fluorescence emission of MOF, 
mitochondria, and DNA, respectively. Images were acquired using custom SIM software previously 
published57. Nine raw images were collected at each plane and recombined using a custom 
implementation of the fairSIM algorithm58. 
Cell culture. MCF-7 cells were cultured at 37 ºC with 5% CO2 in high rich glucose (4500 mg/L) 
DMEM with phenol red supplemented with 10% (v/v) FBS, 2 mM L-glutamine, 100 units/mL 
penicillin and 100 μg/mL streptomycin. This was named complete DMEM (cDMEM). The cells 
were passaged three times a week, whenever the cells reached 70-80% confluency. 
Cytotoxicity assays. MCF-7 cells were seed in 96-well plates at a density of 7,500 cells/well and 
were cultured at 37 ºC with 5% CO2 for 24 h.  
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MTS viability assay. The concentration- and time-dependent viability of cells in the presence of 
DCAx-UiO-66, DCA5-TPP5-UiO-66, TPP@(DCAx-UiO-66), TPP, and DCA was investigated using 
the CellTiter 96® Aqueous Non-Radioactive Cell Proliferation Assay (Promega, UK). The day after 
seeding the cells, the different MOFs and drugs were dispersed in complete medium and a range of 
concentrations was prepared (0–1 mg/mL), of which 100 µL were added to each well and incubated 
for 4–72 h at 37 ºC with 5% CO2. At the end of the incubation period, the treatment solutions were 
removed. The cells were washed once with PBS, and then 100 µL of fresh growth media was added 
to each well. To measure the toxicity, 20 µL of MTS solution were added to each well. The plate 
was then covered with aluminium foil, and placed at 37 ºC and 5% CO2 for 75 min. Then, 100 µL 
of solution from each well were transferred to a new 96-well plate. The plate was read by UV/Vis 
spectroscopy 
Caspase activity. Caspase 3/7, 8, and 9 activity in the presence of DCA5-UiO-66, TPP@(DCA5-
UiO-66) and DCA5-TPP5-UiO-66 was assessed using the Caspase- Glow® assay system (Promega, 
UK). Cells were incubated in the presence of varying concentrations of MOF at 4h and 8h. Caspase 
activity was then assessed according to the manufacturer’s instructions using a TECAN Spark™ 
microplate reader. Experiments were done in quintuplicate. 
Co-localisation with mitochondria. Cells were seeded at 100,000 cells/well in a 4-well chambered 
cell culture cover glass and left to grow for 24 h. They were then transfected with CellLight™ 
Mitochondria-GFP BacMam 2.0 and left to incubate overnight. The cells were then incubated with 
fTPP@(DCA5-UiO-66) for 2 hours, after which the media was removed, and the wells washed 
twice with PBS. 5 µM of DRAQ5 solution in media were added to the cells and left to incubate at 
room temperature in the dark for 5-30 minutes. The cells were then analyzed directly without 
further washing using a TCS SP5 inverted laser scanning microscope (Leica, Germany). An argon 
laser was used to visualize GFP-stained mitochondria (excitation at 488 nm and emission filter set 
at 505-555 nm). To visualize the stained nucleus, a helium-neon laser was used (excitation at 633 
nm and emission filter set at 650-700 nm). fTPP@(DCA5-UiO-66) was excited using a diode laser 
emitting at 405 nm. Images were taken sequentially. Fluorescent images of cells were acquired as 
described above. Images were then merged and converted to 8-bit RGB format using ImageJ 
software.  
Mitochondrial morphology study: Cells were seeded at 100,000 cells/well in a 4-well chambered 
cell culture cover glass and left to grow for 24 h. They were then transfected with CellLight™ 
Mitochondria-GFP BacMam 2.0 and left to incubate overnight. The cells were then incubated with 
cal@(DCA5-UiO-66) or cal-TPP@(DCA5-UiO-66) for 30 minutes and 8 hours, after which the 
media was removed, and the wells washed twice with PBS. 5 µM of DRAQ5 solution in media 
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were added to the cells and left to incubate at room temperature in the dark for 5-30 minutes. The 
cells were then analyzed directly without further washing using the 3-color Structured Illumination 
Microscope (SIM) setup described above. Mitochondria eccentricity was assessed using a custom-
designed pipeline for Cell Profiler59. Briefly, the tool performed the following actions: Extract the 
mitochondria channel from the central slice of the reconstructed SIM image; apply a median filter 
window size 7 to remove elements of noise; run the ‘IdentifyPrimaryObjects’ plugin to extract 
mitochondria as objects from the image; run the ‘MeasureObjectSizeShape’ plugin to gather 
statistics on detected objects; filter objects with an area less than 20 pixels (34µm2); export filtered 
mitochondria objects to a spreadsheet. The eccentricity column was exported from the spreadsheet 
for further statistical analysis. The one-way ANOVA test was performed using GraphPad Prism 
version 7.04 for Windows to assess the statistical difference of mitochondria eccentricity between 
different experimental conditions.  
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